array:21 [
  "pii" => "X2013251409033669"
  "issn" => "20132514"
  "doi" => "10.3265/Nefrologia.2009.29.6.5346.en.full"
  "estado" => "S300"
  "fechaPublicacion" => "2009-12-01"
  "documento" => "article"
  "licencia" => "http://www.elsevier.com/open-access/userlicense/1.0/"
  "subdocumento" => "fla"
  "cita" => "Nefrologia (English Version). 2009;29:604-7"
  "abierto" => array:3 [
    "ES" => true
    "ES2" => true
    "LATM" => true
  ]
  "gratuito" => true
  "lecturas" => array:2 [
    "total" => 4425
    "formatos" => array:3 [
      "EPUB" => 274
      "HTML" => 3619
      "PDF" => 532
    ]
  ]
  "Traduccion" => array:1 [
    "es" => array:17 [
      "pii" => "X0211699509033661"
      "issn" => "02116995"
      "doi" => "10.3265/Nefrologia.2009.29.6.5346.en.full"
      "estado" => "S300"
      "fechaPublicacion" => "2009-12-01"
      "documento" => "article"
      "licencia" => "http://www.elsevier.com/open-access/userlicense/1.0/"
      "subdocumento" => "fla"
      "cita" => "Nefrologia. 2009;29:604-7"
      "abierto" => array:3 [
        "ES" => true
        "ES2" => true
        "LATM" => true
      ]
      "gratuito" => true
      "lecturas" => array:2 [
        "total" => 10525
        "formatos" => array:3 [
          "EPUB" => 260
          "HTML" => 9611
          "PDF" => 654
        ]
      ]
      "es" => array:12 [
        "idiomaDefecto" => true
        "titulo" => "Remisión molecular de una leucemia mieloide crónica en un paciente con segundo trasplante renal y hepatitis"
        "tienePdf" => "es"
        "tieneTextoCompleto" => "es"
        "tieneResumen" => array:2 [
          0 => "es"
          1 => "en"
        ]
        "paginas" => array:1 [
          0 => array:2 [
            "paginaInicial" => "604"
            "paginaFinal" => "607"
          ]
        ]
        "titulosAlternativos" => array:1 [
          "en" => array:1 [
            "titulo" => "Molecular remission of chronic myeloid leukaemia in a patient with hepatitis and a second kidney transplant"
          ]
        ]
        "contieneResumen" => array:2 [
          "es" => true
          "en" => true
        ]
        "contieneTextoCompleto" => array:1 [
          "es" => true
        ]
        "contienePdf" => array:1 [
          "es" => true
        ]
        "resumenGrafico" => array:2 [
          "original" => 0
          "multimedia" => array:7 [
            "identificador" => "fig1"
            "etiqueta" => "Fig. 1"
            "tipo" => "MULTIMEDIAFIGURA"
            "mostrarFloat" => true
            "mostrarDisplay" => false
            "copyright" => "Elsevier España"
            "figura" => array:1 [
              0 => array:4 [
                "imagen" => "451527_figura1.jpg"
                "Alto" => 275
                "Ancho" => 600
                "Tamanyo" => 78564
              ]
            ]
          ]
        ]
        "autores" => array:1 [
          0 => array:2 [
            "autoresLista" => "M. Castillo-Rama, E. Paz-Artal, C. Grande, P. Martínez-Sánchez, José María Morales, A. Andrés, E. Olavarria, D. Marín"
            "autores" => array:8 [
              0 => array:2 [
                "Iniciales" => "M."
                "apellidos" => "Castillo-Rama"
              ]
              1 => array:2 [
                "Iniciales" => "E."
                "apellidos" => "Paz-Artal"
              ]
              2 => array:2 [
                "Iniciales" => "C."
                "apellidos" => "Grande"
              ]
              3 => array:2 [
                "Iniciales" => "P."
                "apellidos" => "Martínez-Sánchez"
              ]
              4 => array:2 [
                "nombre" => "José María"
                "apellidos" => "Morales"
              ]
              5 => array:2 [
                "Iniciales" => "A."
                "apellidos" => "Andrés"
              ]
              6 => array:2 [
                "Iniciales" => "E."
                "apellidos" => "Olavarria"
              ]
              7 => array:2 [
                "Iniciales" => "D."
                "apellidos" => "Marín"
              ]
            ]
          ]
        ]
      ]
      "idiomaDefecto" => "es"
      "Traduccion" => array:1 [
        "en" => array:9 [
          "pii" => "X2013251409033669"
          "doi" => "10.3265/Nefrologia.2009.29.6.5346.en.full"
          "estado" => "S300"
          "subdocumento" => ""
          "abierto" => array:3 [
            "ES" => true
            "ES2" => true
            "LATM" => true
          ]
          "gratuito" => true
          "lecturas" => array:1 [
            "total" => 0
          ]
          "idiomaDefecto" => "en"
          "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/X2013251409033669?idApp=UINPBA000064"
        ]
      ]
      "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/X0211699509033661?idApp=UINPBA000064"
      "url" => "/02116995/0000002900000006/v0_201502091341/X0211699509033661/v0_201502091342/es/main.assets"
    ]
  ]
  "itemSiguiente" => array:17 [
    "pii" => "X2013251409033642"
    "issn" => "20132514"
    "doi" => "10.3265/Nefrologia.2009.29.6.5611.en.full"
    "estado" => "S300"
    "fechaPublicacion" => "2009-12-01"
    "documento" => "article"
    "licencia" => "http://www.elsevier.com/open-access/userlicense/1.0/"
    "subdocumento" => "fla"
    "cita" => "Nefrologia (English Version). 2009;29:608-9"
    "abierto" => array:3 [
      "ES" => true
      "ES2" => true
      "LATM" => true
    ]
    "gratuito" => true
    "lecturas" => array:2 [
      "total" => 3238
      "formatos" => array:3 [
        "EPUB" => 253
        "HTML" => 2511
        "PDF" => 474
      ]
    ]
    "en" => array:9 [
      "idiomaDefecto" => true
      "titulo" => "Continuous extrarenal treatment without anticoagulation therapy"
      "tienePdf" => "en"
      "tieneTextoCompleto" => "en"
      "paginas" => array:1 [
        0 => array:2 [
          "paginaInicial" => "608"
          "paginaFinal" => "609"
        ]
      ]
      "titulosAlternativos" => array:1 [
        "es" => array:1 [
          "titulo" => "Depuración extrarrenal continua sin anticoagulación"
        ]
      ]
      "contieneTextoCompleto" => array:1 [
        "en" => true
      ]
      "contienePdf" => array:1 [
        "en" => true
      ]
      "autores" => array:1 [
        0 => array:2 [
          "autoresLista" => "Luciano Santana Cabrera, M. Sánchez Palacios, A. Ramírez Rodríguez, A. Villanueva Ortiz"
          "autores" => array:4 [
            0 => array:2 [
              "nombre" => "Luciano"
              "apellidos" => "Santana Cabrera"
            ]
            1 => array:2 [
              "Iniciales" => "M."
              "apellidos" => "Sánchez Palacios"
            ]
            2 => array:2 [
              "Iniciales" => "A."
              "apellidos" => "Ramírez Rodríguez"
            ]
            3 => array:2 [
              "Iniciales" => "A."
              "apellidos" => "Villanueva Ortiz"
            ]
          ]
        ]
      ]
    ]
    "idiomaDefecto" => "en"
    "Traduccion" => array:1 [
      "es" => array:9 [
        "pii" => "X0211699509033645"
        "doi" => "10.3265/Nefrologia.2009.29.6.5611.en.full"
        "estado" => "S300"
        "subdocumento" => ""
        "abierto" => array:3 [
          "ES" => true
          "ES2" => true
          "LATM" => true
        ]
        "gratuito" => true
        "lecturas" => array:1 [
          "total" => 0
        ]
        "idiomaDefecto" => "es"
        "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/X0211699509033645?idApp=UINPBA000064"
      ]
    ]
    "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/X2013251409033642?idApp=UINPBA000064"
    "url" => "/20132514/0000002900000006/v0_201502091611/X2013251409033642/v0_201502091612/en/main.assets"
  ]
  "itemAnterior" => array:17 [
    "pii" => "X2013251409033489"
    "issn" => "20132514"
    "doi" => "10.3265/Nefrologia.2009.29.6.5672.en.full"
    "estado" => "S300"
    "fechaPublicacion" => "2009-12-01"
    "documento" => "article"
    "licencia" => "http://www.elsevier.com/open-access/userlicense/1.0/"
    "subdocumento" => "fla"
    "cita" => "Nefrologia (English Version). 2009;29:594-603"
    "abierto" => array:3 [
      "ES" => true
      "ES2" => true
      "LATM" => true
    ]
    "gratuito" => true
    "lecturas" => array:2 [
      "total" => 6404
      "formatos" => array:3 [
        "EPUB" => 247
        "HTML" => 5485
        "PDF" => 672
      ]
    ]
    "en" => array:10 [
      "idiomaDefecto" => true
      "titulo" => "Convection versus diffusion: Is it time to make the change?"
      "tienePdf" => "en"
      "tieneTextoCompleto" => "en"
      "paginas" => array:1 [
        0 => array:2 [
          "paginaInicial" => "594"
          "paginaFinal" => "603"
        ]
      ]
      "titulosAlternativos" => array:1 [
        "es" => array:1 [
          "titulo" => "Convección versus difusión: ¿ha llegado el momento del cambio?"
        ]
      ]
      "contieneTextoCompleto" => array:1 [
        "en" => true
      ]
      "contienePdf" => array:1 [
        "en" => true
      ]
      "resumenGrafico" => array:2 [
        "original" => 0
        "multimedia" => array:8 [
          "identificador" => "fig1"
          "etiqueta" => "Tab.  1"
          "tipo" => "MULTIMEDIAFIGURA"
          "mostrarFloat" => true
          "mostrarDisplay" => false
          "copyright" => "Elsevier España"
          "figura" => array:1 [
            0 => array:4 [
              "imagen" => "44418078_t1_p596.jpg"
              "Alto" => 367
              "Ancho" => 826
              "Tamanyo" => 54252
            ]
          ]
          "descripcion" => array:1 [
            "en" => "Comparative studies between convective techniques and haemodialysis"
          ]
        ]
      ]
      "autores" => array:1 [
        0 => array:2 [
          "autoresLista" => "José Luis Teruel Briones"
          "autores" => array:1 [
            0 => array:2 [
              "nombre" => "José Luis"
              "apellidos" => "Teruel Briones"
            ]
          ]
        ]
      ]
    ]
    "idiomaDefecto" => "en"
    "Traduccion" => array:1 [
      "es" => array:9 [
        "pii" => "X0211699509033481"
        "doi" => "10.3265/Nefrologia.2009.29.6.5672.en.full"
        "estado" => "S300"
        "subdocumento" => ""
        "abierto" => array:3 [
          "ES" => true
          "ES2" => true
          "LATM" => true
        ]
        "gratuito" => true
        "lecturas" => array:1 [
          "total" => 0
        ]
        "idiomaDefecto" => "es"
        "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/X0211699509033481?idApp=UINPBA000064"
      ]
    ]
    "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/X2013251409033489?idApp=UINPBA000064"
    "url" => "/20132514/0000002900000006/v0_201502091611/X2013251409033489/v0_201502091612/en/main.assets"
  ]
  "en" => array:15 [
    "idiomaDefecto" => true
    "titulo" => "Molecular remission of chronic myeloid leukaemia in a patient with hepatitis and a second kidney transplant"
    "tieneTextoCompleto" => true
    "paginas" => array:1 [
      0 => array:2 [
        "paginaInicial" => "604"
        "paginaFinal" => "607"
      ]
    ]
    "autores" => array:1 [
      0 => array:3 [
        "autoresLista" => "M. Castillo-Rama, E. Paz-Artal, C. Grande, P. Martínez-Sánchez, José María Morales, A. Andrés, E. Olavarria, D. Marín"
        "autores" => array:8 [
          0 => array:3 [
            "Iniciales" => "M."
            "apellidos" => "Castillo-Rama"
            "referencia" => array:1 [
              0 => array:2 [
                "etiqueta" => "<span class="elsevierStyleSup">a</span>"
                "identificador" => "affa"
              ]
            ]
          ]
          1 => array:3 [
            "Iniciales" => "E."
            "apellidos" => "Paz-Artal"
            "referencia" => array:1 [
              0 => array:2 [
                "etiqueta" => "<span class="elsevierStyleSup">a</span>"
                "identificador" => "affa"
              ]
            ]
          ]
          2 => array:3 [
            "Iniciales" => "C."
            "apellidos" => "Grande"
            "referencia" => array:1 [
              0 => array:2 [
                "etiqueta" => "<span class="elsevierStyleSup">b</span>"
                "identificador" => "affb"
              ]
            ]
          ]
          3 => array:3 [
            "Iniciales" => "P."
            "apellidos" => "Mart&#237;nez-S&#225;nchez"
            "referencia" => array:1 [
              0 => array:2 [
                "etiqueta" => "<span class="elsevierStyleSup">b</span>"
                "identificador" => "affb"
              ]
            ]
          ]
          4 => array:4 [
            "nombre" => "Jos&#233; Mar&#237;a"
            "apellidos" => "Morales"
            "email" => array:1 [
              0 => "josemariamoralesc&#64;yahoo&#46;es"
            ]
            "referencia" => array:1 [
              0 => array:2 [
                "etiqueta" => "<span class="elsevierStyleSup">c</span>"
                "identificador" => "affc"
              ]
            ]
          ]
          5 => array:3 [
            "Iniciales" => "A."
            "apellidos" => "Andr&#233;s"
            "referencia" => array:1 [
              0 => array:2 [
                "etiqueta" => "<span class="elsevierStyleSup">c</span>"
                "identificador" => "affc"
              ]
            ]
          ]
          6 => array:3 [
            "Iniciales" => "E."
            "apellidos" => "Olavarria"
            "referencia" => array:1 [
              0 => array:2 [
                "etiqueta" => "<span class="elsevierStyleSup">d</span>"
                "identificador" => "affd"
              ]
            ]
          ]
          7 => array:3 [
            "Iniciales" => "D."
            "apellidos" => "Mar&#237;n"
            "referencia" => array:1 [
              0 => array:2 [
                "etiqueta" => "<span class="elsevierStyleSup">d</span>"
                "identificador" => "affd"
              ]
            ]
          ]
        ]
        "afiliaciones" => array:4 [
          0 => array:3 [
            "entidad" => "Servicio de Inmunología, Hospital 12 de Octubre, Madrid, Madrid, España, "
            "etiqueta" => "<span class="elsevierStyleSup">a</span>"
            "identificador" => "affa"
          ]
          1 => array:3 [
            "entidad" => "Servicio de Hematología, Hospital 12 de Octubre, Madrid, Madrid, España, "
            "etiqueta" => "<span class="elsevierStyleSup">b</span>"
            "identificador" => "affb"
          ]
          2 => array:3 [
            "entidad" => "Servicio de Nefrología/Trasplante Renal, Hospital 12 de Octubre, Madrid, Madrid, España, "
            "etiqueta" => "<span class="elsevierStyleSup">c</span>"
            "identificador" => "affc"
          ]
          3 => array:3 [
            "entidad" => "Servicio de Hematología y Área de Terapia Celular, Hammersmith Hospital, Imperial College, Londres, Inglaterra, Gran Bretaña, "
            "etiqueta" => "<span class="elsevierStyleSup">d</span>"
            "identificador" => "affd"
          ]
        ]
      ]
    ]
    "titulosAlternativos" => array:1 [
      "es" => array:1 [
        "titulo" => "Remisi&#243;n molecular de una leucemia mieloide cr&#243;nica en un paciente con segundo trasplante renal y hepatitis"
      ]
    ]
    "resumenGrafico" => array:2 [
      "original" => 0
      "multimedia" => array:7 [
        "identificador" => "fig1"
        "etiqueta" => "Fig. 1"
        "tipo" => "MULTIMEDIAFIGURA"
        "mostrarFloat" => true
        "mostrarDisplay" => false
        "copyright" => "Elsevier Espa&#241;a"
        "figura" => array:1 [
          0 => array:4 [
            "imagen" => "45118078_f1_p605.jpg"
            "Alto" => 372
            "Ancho" => 825
            "Tamanyo" => 29019
          ]
        ]
      ]
    ]
    "textoCompleto" => "<p class="elsevierStylePara"><span class="elsevierStyleBold">INTRODUCTION</span></p><p class="elsevierStylePara">Chronic myeloid leukaemia &#40;CML&#41; is a myeloproliferative disease characterised by clonal expansion of myeloid cells&#46;<span class="elsevierStyleSup">1</span> The pathognomonic cytogenetic anomaly in CML is the Philadelphia chromosome&#44;<span class="elsevierStyleSup">2</span> which is produced by reciprocal translocation of the two long arms of chromosomes 9 and 22&#46;<span class="elsevierStyleSup">3</span> This translocation generates the BC-ABL fusion protein&#44; which is responsible for the oncogenic effects in CML&#46;</p><p class="elsevierStylePara">On only two occasions does the literature describe the use of Imatinib &#40;Gleevec&#44; Novartis&#41;&#44; a BCR-ABL tyrosine kinase inhibitor for CML treatment&#44; in a kidney transplant patient&#59;<span class="elsevierStyleSup">4&#44;5 </span>there are no described cases in a patient with a second transplant with hepatitis C and high cardiovascular and immunological risk&#46;</p><p class="elsevierStylePara"><span class="elsevierStyleBold">CASE REPORT</span></p><p class="elsevierStylePara">Male patient 55 years of age with CML that reached the chronic stage following his second kidney transplant&#46; The patient started haemodialysis for mesangiocapillary glomerulonephritis in 1976 when he was 24&#44; and received a kidney transplant from a live donor in 1983&#46; His immunosupressive treatment was azathioprine and steroids&#46; In 1989&#44; six years after the first transplant&#44; he suffered an acute myocardial infarction&#46; Two years later&#44; he began haemodialysis treatment once again due to chronic rejection of the allograft&#46;</p><p class="elsevierStylePara">In 1994&#44; when the patient was 42&#44; he received a second kidney transplant from a 44 year old female donor&#46; The donor and the recipient share three HLA alleles &#40;HLA A3&#44; B8 and DR3&#41;&#46; The panel reactive antibody &#40;PRA&#41; score was 29&#37;&#44; probably due to various blood transfusions during the course of the first transplant&#44; and to the transplanted organ itself&#46; Immunosuppressants initially administered following the second transplant consisted of steroids &#40;0&#46;5mg&#47;kg&#47;day&#41;&#44; azathioprine &#40;2mg&#47;kg&#47;day&#41; and cyclosporine A &#40;CyA&#41; &#40;10mg&#47;day&#41;&#46;</p><p class="elsevierStylePara">Following the transplant&#44; the patient developed postischaemic acute tubular necrosis&#44; which required two subsequent surgical procedures one month after the transplant to correct a urinary fistula&#46; At the time of the surgical procedure&#44; a kidney biopsy was performed which revealed acute stage 1 rejection&#59; steroids were administered as rescue treatment &#40;1g in four doses&#41;&#46; Two years later&#44; the azathioprine was substituted with mycophenolate &#40;tables 1 and 2&#41; because of decreased renal function with CyA&#46;</p><p class="elsevierStylePara">The patient&#191;s progress was satisfactory until June 2000&#44; when a routine analysis revealed significant leukocytosis &#40;34&#46;5 x 109&#47;l&#41; and thrombocytosis &#40;487 x 109&#47;l&#41; &#40;figure 1&#41;&#46; The patient experienced bilateral hip pain&#44; but had no other symptoms&#46; The examination was normal with no signs of spleen or liver enlargement&#46;</p><p class="elsevierStylePara">An MRI scan of the hip showed diffused bone marrow involvement in almost all bones&#46; The bone marrow aspiration and biopsy confirmed granulocytic and megakaryocytic hyperplasia compatible with CML&#46; No fibrosis was observed in the bone marrow and the patient was low-risk according to the Sokal index&#46;</p><p class="elsevierStylePara">The presence of the Philadelphia chromosome &#40;46XY t&#91;9&#59;22&#93;&#91;q34&#59;q11&#93;&#41; was detected by analysing the bone marrow karyotype&#46; Subsequent cytogenic molecular analyses with fluorescent in situ hybridation &#40;FISH&#41; revealed the presence of the BCR-ABL fusion gene in 90&#37; of the nuclei&#46; The RT-PCR confirmed the typical rearrangement of p210 BCR-ABL with the fusion transcript b2a2&#46; During two months&#44; the patient was treated with hydroxyurea&#44; with no results&#46; In September of this year&#44; the patient was placed in a clinical trial of Novartis STI571-0113 and received 400mg of Imatinib daily&#59; he showed a good tolerance of the drug with no adverse effects&#46; The patient went into complete&#44; sustained haematological remission&#44; complete cytogenetic remission&#44; and molecular remission at two&#44; six and nine months respectively&#44; and this continues to be the case today &#40;figure 2&#41;&#46; Fourteen years after his second transplant&#44; the patient maintains an acceptable level of renal function &#40;stage III chronic renal disease&#41; and has not experienced acute rejection&#44; decreased hepatic function or new cardiovascular events &#40;table 1&#41;&#46;</p><p class="elsevierStylePara"><span class="elsevierStyleBold">DISCUSSION</span></p><p class="elsevierStylePara">This case shows that Imatinib is a safe&#44; effective drug for the treatment of CML in kidney transplant patients&#46; Our patient responded rapidly to the treatment&#58; peripheral blood and bone marrow became normal in the first two months&#44; and cytogenetic and molecular remission occurred during the first year of treatment&#46; These results are in line with IRIS1 study&#44; which showed a complete cytogenetic response in 89&#37; of patients with a low Sokal index&#44; and a survival rate of 83&#37;&#46; Lastly&#44; that study and our patient&#191;s case both show that an early cytogenetic and molecular response is associated with better long-term evolution and a lower risk of progression to the accelerated phase or blast crisis&#46;<span class="elsevierStyleSup">6</span></p><p class="elsevierStylePara">The use of Imatinib in this patient may also have had a beneficial immunosuppressant effect for the transplanted kidney&#44; as suggested by recent in-vitro and animal studies showing that this drug may have immunomodulating effects&#46; Appel et al&#46; showed that Imatinib can inhibit the differentiation of CD34&#43; stem cells into dendritic cells &#40;DC&#41;&#46; Furthermore&#44; T-cell activation may be inhibited&#44; since DC cells&#191; secretion of cytokines and chemokines decreases&#46;<span class="elsevierStyleSup">7</span> Imatinib also inhibits the development of monocytes and macrophages in bone marrow progenitor cells&#46;<span class="elsevierStyleSup">8 </span>Lastly&#44; Dietz et al&#46; showed that Imatinib can inhibit T-cell proliferation by arresting the proliferation of lymphocytes in G<span class="elsevierStyleInf">0</span> phase&#46;</p><p class="elsevierStylePara">Some studies suggest that imatinib in the presence of cyclosporine can cause renal failure due to acute tubular necrosis&#46;<span class="elsevierStyleSup">10&#44;11</span> Despite receiving both drugs&#44; our patient&#191;s renal function remained stable from the moment when treatment with Imatinib was started&#46; Creatinine levels oscillated between 1&#46;75 and 2&#46;4mg&#47;dl with low levels of proteinuria &#40;the maximum proteinuria level was 0&#46;56g&#47;dl&#41;&#44; &#40;table 1&#41;&#46;</p><p class="elsevierStylePara">Serious hepatic side effects have also been described&#44; including fulminant liver failure associated with imatinib treatment&#46;<span class="elsevierStyleSup">12-15</span> Our patient&#44; who was positive for HCV&#44; experienced no changes in liver function during treatment&#46; Liver function remained within the normal range at all times&#44; despite having detectable HCV RNA in blood plasma&#44; which tends to be the case for most HCV patients following a transplant&#46;<span class="elsevierStyleSup">16</span> &#40;Table 3&#41;&#46;</p><p class="elsevierStylePara">Imatinib&#44; according to the manufacturer&#44; may have adverse effects in cardiac patients due to the risk of heart failure&#46; Our patient&#44; who suffered a myocardial infarction at the age of 37&#44; has experienced no adverse effects and his cardiac stress test this year was normal&#46;</p><p class="elsevierStylePara">We conclude that imatinib is a safe and effective treatment for kidney transplant patients with CML&#46; Furthermore&#44; in vitro and animal studies suggest that the drug may have immunomodulating effects that could be beneficial for a transplant&#46; <br></br></p><p class="elsevierStylePara"><a href="grande&#47;45118078&#95;f1&#95;p605&#46;jpg" class="elsevierStyleCrossRefs"><img src="45118078_f1_p605.jpg"></img></a></p><p class="elsevierStylePara">Figure 1&#46; </p><p class="elsevierStylePara"><a href="grande&#47;45118078&#95;t1&#95;p606&#46;jpg" class="elsevierStyleCrossRefs"><img src="45118078_t1_p606.jpg" alt="Patient&#39;s renal function over the last 13 years"></img></a></p><p class="elsevierStylePara">Table 1&#46; Patient&#39;s renal function over the last 13 years</p><p class="elsevierStylePara"><a href="grande&#47;45118078&#95;t2&#95;606&#46;jpg" class="elsevierStyleCrossRefs"><img src="45118078_t2_606.jpg" alt="Creatinine&#44; cyclosporin &#40;CyA&#41; and mycophenolate &#40;MMF&#41; levels during treatment with imatinib"></img></a></p><p class="elsevierStylePara">Table 2&#46; Creatinine&#44; cyclosporin &#40;CyA&#41; and mycophenolate &#40;MMF&#41; levels during treatment with imatinib</p><p class="elsevierStylePara"><a href="grande&#47;45118078&#95;t3&#95;p606&#46;jpg" class="elsevierStyleCrossRefs"><img src="45118078_t3_p606.jpg" alt="Liver function and hep C status from one month after starting treatment"></img></a></p><p class="elsevierStylePara">Table 3&#46; Liver function and hep C status from one month after starting treatment</p><p class="elsevierStylePara"><a href="grande&#47;45118078&#95;f2&#95;p607&#46;jpg" class="elsevierStyleCrossRefs"><img src="45118078_f2_p607.jpg"></img></a></p><p class="elsevierStylePara">Figure 2&#46; </p>"
    "pdfFichero" => "P-E-S-A451-EN.pdf"
    "tienePdf" => true
    "PalabrasClave" => array:2 [
      "en" => array:2 [
        0 => array:4 [
          "clase" => "keyword"
          "titulo" => "Keywords"
          "identificador" => "xpalclavsec438219"
          "palabras" => array:1 [
            0 => "Chronic myeloid leukemia"
          ]
        ]
        1 => array:4 [
          "clase" => "keyword"
          "titulo" => "Keywords"
          "identificador" => "xpalclavsec438221"
          "palabras" => array:1 [
            0 => "renal transplant"
          ]
        ]
      ]
      "es" => array:2 [
        0 => array:4 [
          "clase" => "keyword"
          "titulo" => "Palabras clave"
          "identificador" => "xpalclavsec438220"
          "palabras" => array:1 [
            0 => "trasplante renal"
          ]
        ]
        1 => array:4 [
          "clase" => "keyword"
          "titulo" => "Palabras clave"
          "identificador" => "xpalclavsec438222"
          "palabras" => array:1 [
            0 => "Leucemia mieloide cr&#243;nica"
          ]
        ]
      ]
    ]
    "tieneResumen" => true
    "resumen" => array:2 [
      "en" => array:1 [
        "resumen" => "Abstract Chronic myeloid leukemia &#40;CML&#41; is a myeloproliferative disorder characterized by clonal expansion of cells in the myeloid line&#44; expressing the BCRABL fusion protein responsible for the oncogenic effect of CML&#46; The current frontline therapy in CML is the BCR-ABL tyrosine kinase inhibitor&#44; Imatinib&#46; Although this drug has been shown to improve survival in CML patients&#44; its role in the context of a transplant setting has not been widely described in the literature&#46; We report on the long term molecular remission of CML in a 55 year old man with a second renal transplant who is hepatitis C virus positive&#44; and has associated cardiovascular and immunological risk factors&#46;"
      ]
      "es" => array:1 [
        "resumen" => "<p class="elsevierStylePara">La leucemia mieloide cr&#243;nica &#40;LMC&#41; es una enfermedad mieloproliferativa caracterizada por la expansi&#243;n clonal de c&#233;lulas mieloides que expresan la prote&#237;na de fusi&#243;n BCR-ABL&#44; responsable de los efectos oncog&#233;nicos de la LMC&#46; La terapia actual en el tratamiento de LMC es el inhibidor de la BCR-ABL tiros&#237;n-kinasa&#44; imatinib&#46; Aunque este f&#225;rmaco ha demostrado mejorar la supervivencia en pacientes con LMC&#44; su papel en el contexto del trasplante renal no ha sido ampliamente descrito en la literatura&#46; Presentamos un caso de remisi&#243;n molecular de LMC en un var&#243;n de 55 a&#241;os con un segundo trasplante renal&#44; hepatitis C y con riesgos cardiovasculares e inmunol&#243;gicos asociados&#46;</p>"
      ]
    ]
    "multimedia" => array:5 [
      0 => array:7 [
        "identificador" => "fig1"
        "etiqueta" => "Fig. 1"
        "tipo" => "MULTIMEDIAFIGURA"
        "mostrarFloat" => true
        "mostrarDisplay" => false
        "copyright" => "Elsevier Espa&#241;a"
        "figura" => array:1 [
          0 => array:4 [
            "imagen" => "45118078_f1_p605.jpg"
            "Alto" => 372
            "Ancho" => 825
            "Tamanyo" => 29019
          ]
        ]
      ]
      1 => array:8 [
        "identificador" => "fig2"
        "etiqueta" => "Tab.  1"
        "tipo" => "MULTIMEDIAFIGURA"
        "mostrarFloat" => true
        "mostrarDisplay" => false
        "copyright" => "Elsevier Espa&#241;a"
        "figura" => array:1 [
          0 => array:4 [
            "imagen" => "45118078_t1_p606.jpg"
            "Alto" => 134
            "Ancho" => 826
            "Tamanyo" => 23808
          ]
        ]
        "descripcion" => array:1 [
          "en" => "Patient&#39;s renal function over the last 13 years"
        ]
      ]
      2 => array:8 [
        "identificador" => "fig3"
        "etiqueta" => "Tab.  2"
        "tipo" => "MULTIMEDIAFIGURA"
        "mostrarFloat" => true
        "mostrarDisplay" => false
        "copyright" => "Elsevier Espa&#241;a"
        "figura" => array:1 [
          0 => array:4 [
            "imagen" => "45118078_t2_606.jpg"
            "Alto" => 156
            "Ancho" => 826
            "Tamanyo" => 29652
          ]
        ]
        "descripcion" => array:1 [
          "en" => "Creatinine&#44; cyclosporin &#40;CyA&#41; and mycophenolate &#40;MMF&#41; levels during treatment with imatinib"
        ]
      ]
      3 => array:8 [
        "identificador" => "fig4"
        "etiqueta" => "Tab.  3"
        "tipo" => "MULTIMEDIAFIGURA"
        "mostrarFloat" => true
        "mostrarDisplay" => false
        "copyright" => "Elsevier Espa&#241;a"
        "figura" => array:1 [
          0 => array:4 [
            "imagen" => "45118078_t3_p606.jpg"
            "Alto" => 233
            "Ancho" => 827
            "Tamanyo" => 40890
          ]
        ]
        "descripcion" => array:1 [
          "en" => "Liver function and hep C status from one month after starting treatment"
        ]
      ]
      4 => array:7 [
        "identificador" => "fig5"
        "etiqueta" => "Fig. 2"
        "tipo" => "MULTIMEDIAFIGURA"
        "mostrarFloat" => true
        "mostrarDisplay" => false
        "copyright" => "Elsevier Espa&#241;a"
        "figura" => array:1 [
          0 => array:4 [
            "imagen" => "45118078_f2_p607.jpg"
            "Alto" => 368
            "Ancho" => 824
            "Tamanyo" => 25738
          ]
        ]
      ]
    ]
    "bibliografia" => array:2 [
      "titulo" => "Bibliography"
      "seccion" => array:1 [
        0 => array:1 [
          "bibliografiaReferencia" => array:16 [
            0 => array:3 [
              "identificador" => "bib1"
              "etiqueta" => "1"
              "referencia" => array:1 [
                0 => array:3 [
                  "referenciaCompleta" => "Druker BJ, Talpaz M, Resta DJ, Peng B, Buchdunger E, Ford JM, et al. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med 2001;344(14):1031-7. <a href="http://www.ncbi.nlm.nih.gov/pubmed/11287972" target="_blank">[Pubmed]</a>"
                  "contribucion" => array:1 [
                    0 => null
                  ]
                  "host" => array:1 [
                    0 => array:1 [
                      "Revista" => array:1 [
                        "itemHostRev" => array:3 [
                          "pii" => "S1525861013000388"
                          "estado" => "S300"
                          "issn" => "15258610"
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            1 => array:3 [
              "identificador" => "bib2"
              "etiqueta" => "2"
              "referencia" => array:1 [
                0 => array:3 [
                  "referenciaCompleta" => "Nowell PC, Hungerford DA. Chromosome studies in human leukemia. II. Chronic granulocytic leukemia. J Natl Cancer Inst 1961;27:1013-35. <a href="http://www.ncbi.nlm.nih.gov/pubmed/14480645" target="_blank">[Pubmed]</a>"
                  "contribucion" => array:1 [
                    0 => null
                  ]
                  "host" => array:1 [
                    0 => null
                  ]
                ]
              ]
            ]
            2 => array:3 [
              "identificador" => "bib3"
              "etiqueta" => "3"
              "referencia" => array:1 [
                0 => array:3 [
                  "referenciaCompleta" => "Rowley JD. Letter: A new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and Giemsa staining. Nature 1973;243(5405):290-3. <a href="http://www.ncbi.nlm.nih.gov/pubmed/4126434" target="_blank">[Pubmed]</a>"
                  "contribucion" => array:1 [
                    0 => null
                  ]
                  "host" => array:1 [
                    0 => null
                  ]
                ]
              ]
            ]
            3 => array:3 [
              "identificador" => "bib4"
              "etiqueta" => "4"
              "referencia" => array:1 [
                0 => array:3 [
                  "referenciaCompleta" => "Koca E, Cetiner D, Goker H, Aksu S, Ozcebe OI, Haznedaroglu IC, et al. Complete cytogenietic remission with imatinib mesylate treatment in chronic myelogenous leukemia (CML) developed after renal transplantation Clin Nephrol 2005;64(4):324-6. <a href="http://www.ncbi.nlm.nih.gov/pubmed/16240908" target="_blank">[Pubmed]</a>"
                  "contribucion" => array:1 [
                    0 => null
                  ]
                  "host" => array:1 [
                    0 => null
                  ]
                ]
              ]
            ]
            4 => array:3 [
              "identificador" => "bib5"
              "etiqueta" => "5"
              "referencia" => array:1 [
                0 => array:3 [
                  "referenciaCompleta" => "Thierry A, Dreyfus B, Bridoux F, Abou Ayache R, Milin S, Guilhot F, et al. Long-term molecular efficacy and safety of imatinib in a patient with chronic myeloid leukaemia after renal transplantation. Nephrol Dial Transplant 2007;22(6):1791-2. <a href="http://www.ncbi.nlm.nih.gov/pubmed/17308316" target="_blank">[Pubmed]</a>"
                  "contribucion" => array:1 [
                    0 => null
                  ]
                  "host" => array:1 [
                    0 => null
                  ]
                ]
              ]
            ]
            5 => array:3 [
              "identificador" => "bib6"
              "etiqueta" => "6"
              "referencia" => array:1 [
                0 => array:3 [
                  "referenciaCompleta" => "Druker BJ, Guilhot F, O¿Brien SG, Gathmann I, Kantarjian H, Gattermann N, et al.; IRIS Investigators. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med 2006;355(23):2408-17. <a href="http://www.ncbi.nlm.nih.gov/pubmed/17151364" target="_blank">[Pubmed]</a>"
                  "contribucion" => array:1 [
                    0 => null
                  ]
                  "host" => array:1 [
                    0 => null
                  ]
                ]
              ]
            ]
            6 => array:3 [
              "identificador" => "bib7"
              "etiqueta" => "7"
              "referencia" => array:1 [
                0 => array:3 [
                  "referenciaCompleta" => "Appel S, Balabanov S, Brümmendorf TH, Brossart P. Effects of imatinib on normal hematopoiesis and immune activation. Stem Cells 2005;23(8):1082-8. <a href="http://www.ncbi.nlm.nih.gov/pubmed/16140870" target="_blank">[Pubmed]</a>"
                  "contribucion" => array:1 [
                    0 => null
                  ]
                  "host" => array:1 [
                    0 => null
                  ]
                ]
              ]
            ]
            7 => array:3 [
              "identificador" => "bib8"
              "etiqueta" => "8"
              "referencia" => array:1 [
                0 => array:3 [
                  "referenciaCompleta" => "Dewar AL, Doherty KV, Hughes TP, Lyons AB. Imatinib inhibits the functional capacity of cultured human monocytes. Immunol Cell Biol 2005;83(1):48-56. <a href="http://www.ncbi.nlm.nih.gov/pubmed/15661041" target="_blank">[Pubmed]</a>"
                  "contribucion" => array:1 [
                    0 => null
                  ]
                  "host" => array:1 [
                    0 => null
                  ]
                ]
              ]
            ]
            8 => array:3 [
              "identificador" => "bib9"
              "etiqueta" => "9"
              "referencia" => array:1 [
                0 => array:3 [
                  "referenciaCompleta" => "Dietz AB, Souan L, Knutson GJ, Bulur PA, Litzow MR, Vuk-Pavlovic S. Imatinib mesylate inhibits T-cell proliferation in vitro and delayed-type hypersensitivity in vivo. Blood 2004;104(4):1094-9. <a href="http://www.ncbi.nlm.nih.gov/pubmed/15100154" target="_blank">[Pubmed]</a>"
                  "contribucion" => array:1 [
                    0 => null
                  ]
                  "host" => array:1 [
                    0 => null
                  ]
                ]
              ]
            ]
            9 => array:3 [
              "identificador" => "bib10"
              "etiqueta" => "10"
              "referencia" => array:1 [
                0 => array:3 [
                  "referenciaCompleta" => "Kitiyakara C, Atichartakarn V. Renal failure associated with a specific inhibitor of BCR-ABL tyrosine kinase, STI 571. Nephrol Dial Transplant 2002;17(4):685-7."
                  "contribucion" => array:1 [
                    0 => null
                  ]
                  "host" => array:1 [
                    0 => null
                  ]
                ]
              ]
            ]
            10 => array:3 [
              "identificador" => "bib11"
              "etiqueta" => "11"
              "referencia" => array:1 [
                0 => array:3 [
                  "referenciaCompleta" => "Pou M, Saval N, Vera M, Saurina A, Solé M, Cervantes F, et al. Acute renal failure secondary to imatinib mesylate treatment in chronic myeloid leukemia. Leuk Lymphoma 2003;44(7):1239-41. <a href="http://www.ncbi.nlm.nih.gov/pubmed/12916879" target="_blank">[Pubmed]</a>"
                  "contribucion" => array:1 [
                    0 => null
                  ]
                  "host" => array:1 [
                    0 => null
                  ]
                ]
              ]
            ]
            11 => array:3 [
              "identificador" => "bib12"
              "etiqueta" => "12"
              "referencia" => array:1 [
                0 => array:3 [
                  "referenciaCompleta" => "Chen L, Wang JM, Xu XP Gao L, Fei XH, Lou JW, et al. The reverse effect on drug-resistance against tyrosine kinase inhibitor STI571 in mdr1 and bcr-abl positive leukemic cells. Zhongguo Shi Yan Xue Ye Xue Za Zhi (Abstract) 2003;11(6):600-3."
                  "contribucion" => array:1 [
                    0 => null
                  ]
                  "host" => array:1 [
                    0 => array:1 [
                      "Revista" => array:1 [
                        "itemHostRev" => array:3 [
                          "pii" => "S1525861011002568"
                          "estado" => "S300"
                          "issn" => "15258610"
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            12 => array:3 [
              "identificador" => "bib13"
              "etiqueta" => "13"
              "referencia" => array:1 [
                0 => array:3 [
                  "referenciaCompleta" => "Ridruejo E, Cacchione R, Villamil AG, Marciano S, Gadano AC, Mando OG. Imatinib-induced fatal acute liver failure. World J Gastroenterol 2007;13(48):6608-11."
                  "contribucion" => array:1 [
                    0 => null
                  ]
                  "host" => array:1 [
                    0 => null
                  ]
                ]
              ]
            ]
            13 => array:3 [
              "identificador" => "bib14"
              "etiqueta" => "14"
              "referencia" => array:1 [
                0 => array:3 [
                  "referenciaCompleta" => "Cross TJ, Bagot C, Portmann B, Wendon J, Gillett D. Imatinib mesylate as a cause of acute liver failure. Am J Hematol 2006;81(3):189-92. <a href="http://www.ncbi.nlm.nih.gov/pubmed/16493605" target="_blank">[Pubmed]</a>"
                  "contribucion" => array:1 [
                    0 => null
                  ]
                  "host" => array:1 [
                    0 => array:1 [
                      "Revista" => array:1 [
                        "itemHostRev" => array:3 [
                          "pii" => "S1525861013003022"
                          "estado" => "S300"
                          "issn" => "15258610"
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            14 => array:3 [
              "identificador" => "bib15"
              "etiqueta" => "15"
              "referencia" => array:1 [
                0 => array:3 [
                  "referenciaCompleta" => "Al Sobhi E, Zahrani Z, Zevallos E, Zuraiki A. Imatinib-induced immune hepatitis: case report and literature review. Hematology 2007;12(1):49-53. <a href="http://www.ncbi.nlm.nih.gov/pubmed/17364993" target="_blank">[Pubmed]</a>"
                  "contribucion" => array:1 [
                    0 => null
                  ]
                  "host" => array:1 [
                    0 => null
                  ]
                ]
              ]
            ]
            15 => array:3 [
              "identificador" => "bib16"
              "etiqueta" => "16"
              "referencia" => array:1 [
                0 => array:3 [
                  "referenciaCompleta" => "Morales JM, Campistol JM.Transplantation in the Patient with Hepatitis C. J Am Soc Nephrol 2000;11:1343-53.  <a href="http://www.ncbi.nlm.nih.gov/pubmed/10864593" target="_blank">[Pubmed]</a>"
                  "contribucion" => array:1 [
                    0 => null
                  ]
                  "host" => array:1 [
                    0 => null
                  ]
                ]
              ]
            ]
          ]
        ]
      ]
    ]
  ]
  "idiomaDefecto" => "en"
  "url" => "/20132514/0000002900000006/v0_201502091611/X2013251409033669/v0_201502091612/en/main.assets"
  "Apartado" => array:4 [
    "identificador" => "35422"
    "tipo" => "SECCION"
    "en" => array:2 [
      "titulo" => "Case Reports"
      "idiomaDefecto" => true
    ]
    "idiomaDefecto" => "en"
  ]
  "PDF" => "https://static.elsevier.es/multimedia/20132514/0000002900000006/v0_201502091611/X2013251409033669/v0_201502091612/en/P-E-S-A451-EN.pdf?idApp=UINPBA000064&text.app=https://revistanefrologia.com/"
  "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/X2013251409033669?idApp=UINPBA000064"
]
Share
Journal Information

Statistics

Follow this link to access the full text of the article

Molecular remission of chronic myeloid leukaemia in a patient with hepatitis and a second kidney transplant
Remisión molecular de una leucemia mieloide crónica en un paciente con segundo trasplante renal y hepatitis
M.. Castillo-Ramaa, E.. Paz-Artala, C.. Grandeb, P.. Martínez-Sánchezb, José María Moralesc, A.. Andrésc, E.. Olavarriad, D.. Marínd
a Servicio de Inmunología, Hospital 12 de Octubre, Madrid, Madrid, España,
b Servicio de Hematología, Hospital 12 de Octubre, Madrid, Madrid, España,
c Servicio de Nefrología/Trasplante Renal, Hospital 12 de Octubre, Madrid, Madrid, España,
d Servicio de Hematología y Área de Terapia Celular, Hammersmith Hospital, Imperial College, Londres, Inglaterra, Gran Bretaña,
Read
8465
Times
was read the article
2251
Total PDF
6214
Total HTML
Share statistics
 array:21 [
  "pii" => "X2013251409033669"
  "issn" => "20132514"
  "doi" => "10.3265/Nefrologia.2009.29.6.5346.en.full"
  "estado" => "S300"
  "fechaPublicacion" => "2009-12-01"
  "documento" => "article"
  "licencia" => "http://www.elsevier.com/open-access/userlicense/1.0/"
  "subdocumento" => "fla"
  "cita" => "Nefrologia &#40;English Version&#41;. 2009;29:604-7"
  "abierto" => array:3 [
    "ES" => true
    "ES2" => true
    "LATM" => true
  ]
  "gratuito" => true
  "lecturas" => array:2 [
    "total" => 4425
    "formatos" => array:3 [
      "EPUB" => 274
      "HTML" => 3619
      "PDF" => 532
    ]
  ]
  "Traduccion" => array:1 [
    "es" => array:17 [
      "pii" => "X0211699509033661"
      "issn" => "02116995"
      "doi" => "10.3265/Nefrologia.2009.29.6.5346.en.full"
      "estado" => "S300"
      "fechaPublicacion" => "2009-12-01"
      "documento" => "article"
      "licencia" => "http://www.elsevier.com/open-access/userlicense/1.0/"
      "subdocumento" => "fla"
      "cita" => "Nefrologia. 2009;29:604-7"
      "abierto" => array:3 [
        "ES" => true
        "ES2" => true
        "LATM" => true
      ]
      "gratuito" => true
      "lecturas" => array:2 [
        "total" => 10525
        "formatos" => array:3 [
          "EPUB" => 260
          "HTML" => 9611
          "PDF" => 654
        ]
      ]
      "es" => array:12 [
        "idiomaDefecto" => true
        "titulo" => "Remisi&#243;n molecular de una leucemia mieloide cr&#243;nica en un paciente con segundo trasplante renal y hepatitis"
        "tienePdf" => "es"
        "tieneTextoCompleto" => "es"
        "tieneResumen" => array:2 [
          0 => "es"
          1 => "en"
        ]
        "paginas" => array:1 [
          0 => array:2 [
            "paginaInicial" => "604"
            "paginaFinal" => "607"
          ]
        ]
        "titulosAlternativos" => array:1 [
          "en" => array:1 [
            "titulo" => "Molecular remission of chronic myeloid leukaemia in a patient with hepatitis and a second kidney transplant"
          ]
        ]
        "contieneResumen" => array:2 [
          "es" => true
          "en" => true
        ]
        "contieneTextoCompleto" => array:1 [
          "es" => true
        ]
        "contienePdf" => array:1 [
          "es" => true
        ]
        "resumenGrafico" => array:2 [
          "original" => 0
          "multimedia" => array:7 [
            "identificador" => "fig1"
            "etiqueta" => "Fig. 1"
            "tipo" => "MULTIMEDIAFIGURA"
            "mostrarFloat" => true
            "mostrarDisplay" => false
            "copyright" => "Elsevier Espa&#241;a"
            "figura" => array:1 [
              0 => array:4 [
                "imagen" => "451527_figura1.jpg"
                "Alto" => 275
                "Ancho" => 600
                "Tamanyo" => 78564
              ]
            ]
          ]
        ]
        "autores" => array:1 [
          0 => array:2 [
            "autoresLista" => "M. Castillo-Rama, E. Paz-Artal, C. Grande, P. Mart&#237;nez-S&#225;nchez, Jos&#233; Mar&#237;a Morales, A. Andr&#233;s, E. Olavarria, D. Mar&#237;n"
            "autores" => array:8 [
              0 => array:2 [
                "Iniciales" => "M."
                "apellidos" => "Castillo-Rama"
              ]
              1 => array:2 [
                "Iniciales" => "E."
                "apellidos" => "Paz-Artal"
              ]
              2 => array:2 [
                "Iniciales" => "C."
                "apellidos" => "Grande"
              ]
              3 => array:2 [
                "Iniciales" => "P."
                "apellidos" => "Mart&#237;nez-S&#225;nchez"
              ]
              4 => array:2 [
                "nombre" => "Jos&#233; Mar&#237;a"
                "apellidos" => "Morales"
              ]
              5 => array:2 [
                "Iniciales" => "A."
                "apellidos" => "Andr&#233;s"
              ]
              6 => array:2 [
                "Iniciales" => "E."
                "apellidos" => "Olavarria"
              ]
              7 => array:2 [
                "Iniciales" => "D."
                "apellidos" => "Mar&#237;n"
              ]
            ]
          ]
        ]
      ]
      "idiomaDefecto" => "es"
      "Traduccion" => array:1 [
        "en" => array:9 [
          "pii" => "X2013251409033669"
          "doi" => "10.3265/Nefrologia.2009.29.6.5346.en.full"
          "estado" => "S300"
          "subdocumento" => ""
          "abierto" => array:3 [
            "ES" => true
            "ES2" => true
            "LATM" => true
          ]
          "gratuito" => true
          "lecturas" => array:1 [
            "total" => 0
          ]
          "idiomaDefecto" => "en"
          "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/X2013251409033669?idApp=UINPBA000064"
        ]
      ]
      "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/X0211699509033661?idApp=UINPBA000064"
      "url" => "/02116995/0000002900000006/v0_201502091341/X0211699509033661/v0_201502091342/es/main.assets"
    ]
  ]
  "itemSiguiente" => array:17 [
    "pii" => "X2013251409033642"
    "issn" => "20132514"
    "doi" => "10.3265/Nefrologia.2009.29.6.5611.en.full"
    "estado" => "S300"
    "fechaPublicacion" => "2009-12-01"
    "documento" => "article"
    "licencia" => "http://www.elsevier.com/open-access/userlicense/1.0/"
    "subdocumento" => "fla"
    "cita" => "Nefrologia &#40;English Version&#41;. 2009;29:608-9"
    "abierto" => array:3 [
      "ES" => true
      "ES2" => true
      "LATM" => true
    ]
    "gratuito" => true
    "lecturas" => array:2 [
      "total" => 3238
      "formatos" => array:3 [
        "EPUB" => 253
        "HTML" => 2511
        "PDF" => 474
      ]
    ]
    "en" => array:9 [
      "idiomaDefecto" => true
      "titulo" => "Continuous extrarenal treatment without anticoagulation therapy"
      "tienePdf" => "en"
      "tieneTextoCompleto" => "en"
      "paginas" => array:1 [
        0 => array:2 [
          "paginaInicial" => "608"
          "paginaFinal" => "609"
        ]
      ]
      "titulosAlternativos" => array:1 [
        "es" => array:1 [
          "titulo" => "Depuraci&#243;n extrarrenal continua sin anticoagulaci&#243;n"
        ]
      ]
      "contieneTextoCompleto" => array:1 [
        "en" => true
      ]
      "contienePdf" => array:1 [
        "en" => true
      ]
      "autores" => array:1 [
        0 => array:2 [
          "autoresLista" => "Luciano Santana Cabrera, M. S&#225;nchez Palacios, A. Ram&#237;rez Rodr&#237;guez, A. Villanueva Ortiz"
          "autores" => array:4 [
            0 => array:2 [
              "nombre" => "Luciano"
              "apellidos" => "Santana Cabrera"
            ]
            1 => array:2 [
              "Iniciales" => "M."
              "apellidos" => "S&#225;nchez Palacios"
            ]
            2 => array:2 [
              "Iniciales" => "A."
              "apellidos" => "Ram&#237;rez Rodr&#237;guez"
            ]
            3 => array:2 [
              "Iniciales" => "A."
              "apellidos" => "Villanueva Ortiz"
            ]
          ]
        ]
      ]
    ]
    "idiomaDefecto" => "en"
    "Traduccion" => array:1 [
      "es" => array:9 [
        "pii" => "X0211699509033645"
        "doi" => "10.3265/Nefrologia.2009.29.6.5611.en.full"
        "estado" => "S300"
        "subdocumento" => ""
        "abierto" => array:3 [
          "ES" => true
          "ES2" => true
          "LATM" => true
        ]
        "gratuito" => true
        "lecturas" => array:1 [
          "total" => 0
        ]
        "idiomaDefecto" => "es"
        "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/X0211699509033645?idApp=UINPBA000064"
      ]
    ]
    "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/X2013251409033642?idApp=UINPBA000064"
    "url" => "/20132514/0000002900000006/v0_201502091611/X2013251409033642/v0_201502091612/en/main.assets"
  ]
  "itemAnterior" => array:17 [
    "pii" => "X2013251409033489"
    "issn" => "20132514"
    "doi" => "10.3265/Nefrologia.2009.29.6.5672.en.full"
    "estado" => "S300"
    "fechaPublicacion" => "2009-12-01"
    "documento" => "article"
    "licencia" => "http://www.elsevier.com/open-access/userlicense/1.0/"
    "subdocumento" => "fla"
    "cita" => "Nefrologia &#40;English Version&#41;. 2009;29:594-603"
    "abierto" => array:3 [
      "ES" => true
      "ES2" => true
      "LATM" => true
    ]
    "gratuito" => true
    "lecturas" => array:2 [
      "total" => 6404
      "formatos" => array:3 [
        "EPUB" => 247
        "HTML" => 5485
        "PDF" => 672
      ]
    ]
    "en" => array:10 [
      "idiomaDefecto" => true
      "titulo" => "Convection versus diffusion&#58; Is it time to make the change&#63;"
      "tienePdf" => "en"
      "tieneTextoCompleto" => "en"
      "paginas" => array:1 [
        0 => array:2 [
          "paginaInicial" => "594"
          "paginaFinal" => "603"
        ]
      ]
      "titulosAlternativos" => array:1 [
        "es" => array:1 [
          "titulo" => "Convecci&#243;n versus difusi&#243;n&#58; &#191;ha llegado el momento del cambio&#63;"
        ]
      ]
      "contieneTextoCompleto" => array:1 [
        "en" => true
      ]
      "contienePdf" => array:1 [
        "en" => true
      ]
      "resumenGrafico" => array:2 [
        "original" => 0
        "multimedia" => array:8 [
          "identificador" => "fig1"
          "etiqueta" => "Tab.  1"
          "tipo" => "MULTIMEDIAFIGURA"
          "mostrarFloat" => true
          "mostrarDisplay" => false
          "copyright" => "Elsevier Espa&#241;a"
          "figura" => array:1 [
            0 => array:4 [
              "imagen" => "44418078_t1_p596.jpg"
              "Alto" => 367
              "Ancho" => 826
              "Tamanyo" => 54252
            ]
          ]
          "descripcion" => array:1 [
            "en" => "Comparative studies between convective techniques and haemodialysis"
          ]
        ]
      ]
      "autores" => array:1 [
        0 => array:2 [
          "autoresLista" => "Jos&#233; Luis Teruel Briones"
          "autores" => array:1 [
            0 => array:2 [
              "nombre" => "Jos&#233; Luis"
              "apellidos" => "Teruel Briones"
            ]
          ]
        ]
      ]
    ]
    "idiomaDefecto" => "en"
    "Traduccion" => array:1 [
      "es" => array:9 [
        "pii" => "X0211699509033481"
        "doi" => "10.3265/Nefrologia.2009.29.6.5672.en.full"
        "estado" => "S300"
        "subdocumento" => ""
        "abierto" => array:3 [
          "ES" => true
          "ES2" => true
          "LATM" => true
        ]
        "gratuito" => true
        "lecturas" => array:1 [
          "total" => 0
        ]
        "idiomaDefecto" => "es"
        "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/X0211699509033481?idApp=UINPBA000064"
      ]
    ]
    "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/X2013251409033489?idApp=UINPBA000064"
    "url" => "/20132514/0000002900000006/v0_201502091611/X2013251409033489/v0_201502091612/en/main.assets"
  ]
  "en" => array:15 [
    "idiomaDefecto" => true
    "titulo" => "Molecular remission of chronic myeloid leukaemia in a patient with hepatitis and a second kidney transplant"
    "tieneTextoCompleto" => true
    "paginas" => array:1 [
      0 => array:2 [
        "paginaInicial" => "604"
        "paginaFinal" => "607"
      ]
    ]
    "autores" => array:1 [
      0 => array:3 [
        "autoresLista" => "M. Castillo-Rama, E. Paz-Artal, C. Grande, P. Mart&#237;nez-S&#225;nchez, Jos&#233; Mar&#237;a Morales, A. Andr&#233;s, E. Olavarria, D. Mar&#237;n"
        "autores" => array:8 [
          0 => array:3 [
            "Iniciales" => "M."
            "apellidos" => "Castillo-Rama"
            "referencia" => array:1 [
              0 => array:2 [
                "etiqueta" => "<span class="elsevierStyleSup">a</span>"
                "identificador" => "affa"
              ]
            ]
          ]
          1 => array:3 [
            "Iniciales" => "E."
            "apellidos" => "Paz-Artal"
            "referencia" => array:1 [
              0 => array:2 [
                "etiqueta" => "<span class="elsevierStyleSup">a</span>"
                "identificador" => "affa"
              ]
            ]
          ]
          2 => array:3 [
            "Iniciales" => "C."
            "apellidos" => "Grande"
            "referencia" => array:1 [
              0 => array:2 [
                "etiqueta" => "<span class="elsevierStyleSup">b</span>"
                "identificador" => "affb"
              ]
            ]
          ]
          3 => array:3 [
            "Iniciales" => "P."
            "apellidos" => "Mart&#237;nez-S&#225;nchez"
            "referencia" => array:1 [
              0 => array:2 [
                "etiqueta" => "<span class="elsevierStyleSup">b</span>"
                "identificador" => "affb"
              ]
            ]
          ]
          4 => array:4 [
            "nombre" => "Jos&#233; Mar&#237;a"
            "apellidos" => "Morales"
            "email" => array:1 [
              0 => "josemariamoralesc&#64;yahoo&#46;es"
            ]
            "referencia" => array:1 [
              0 => array:2 [
                "etiqueta" => "<span class="elsevierStyleSup">c</span>"
                "identificador" => "affc"
              ]
            ]
          ]
          5 => array:3 [
            "Iniciales" => "A."
            "apellidos" => "Andr&#233;s"
            "referencia" => array:1 [
              0 => array:2 [
                "etiqueta" => "<span class="elsevierStyleSup">c</span>"
                "identificador" => "affc"
              ]
            ]
          ]
          6 => array:3 [
            "Iniciales" => "E."
            "apellidos" => "Olavarria"
            "referencia" => array:1 [
              0 => array:2 [
                "etiqueta" => "<span class="elsevierStyleSup">d</span>"
                "identificador" => "affd"
              ]
            ]
          ]
          7 => array:3 [
            "Iniciales" => "D."
            "apellidos" => "Mar&#237;n"
            "referencia" => array:1 [
              0 => array:2 [
                "etiqueta" => "<span class="elsevierStyleSup">d</span>"
                "identificador" => "affd"
              ]
            ]
          ]
        ]
        "afiliaciones" => array:4 [
          0 => array:3 [
            "entidad" => "Servicio de Inmunología, Hospital 12 de Octubre, Madrid, Madrid, España, "
            "etiqueta" => "<span class="elsevierStyleSup">a</span>"
            "identificador" => "affa"
          ]
          1 => array:3 [
            "entidad" => "Servicio de Hematología, Hospital 12 de Octubre, Madrid, Madrid, España, "
            "etiqueta" => "<span class="elsevierStyleSup">b</span>"
            "identificador" => "affb"
          ]
          2 => array:3 [
            "entidad" => "Servicio de Nefrología/Trasplante Renal, Hospital 12 de Octubre, Madrid, Madrid, España, "
            "etiqueta" => "<span class="elsevierStyleSup">c</span>"
            "identificador" => "affc"
          ]
          3 => array:3 [
            "entidad" => "Servicio de Hematología y Área de Terapia Celular, Hammersmith Hospital, Imperial College, Londres, Inglaterra, Gran Bretaña, "
            "etiqueta" => "<span class="elsevierStyleSup">d</span>"
            "identificador" => "affd"
          ]
        ]
      ]
    ]
    "titulosAlternativos" => array:1 [
      "es" => array:1 [
        "titulo" => "Remisi&#243;n molecular de una leucemia mieloide cr&#243;nica en un paciente con segundo trasplante renal y hepatitis"
      ]
    ]
    "resumenGrafico" => array:2 [
      "original" => 0
      "multimedia" => array:7 [
        "identificador" => "fig1"
        "etiqueta" => "Fig. 1"
        "tipo" => "MULTIMEDIAFIGURA"
        "mostrarFloat" => true
        "mostrarDisplay" => false
        "copyright" => "Elsevier Espa&#241;a"
        "figura" => array:1 [
          0 => array:4 [
            "imagen" => "45118078_f1_p605.jpg"
            "Alto" => 372
            "Ancho" => 825
            "Tamanyo" => 29019
          ]
        ]
      ]
    ]
    "textoCompleto" => "<p class="elsevierStylePara"><span class="elsevierStyleBold">INTRODUCTION</span></p><p class="elsevierStylePara">Chronic myeloid leukaemia &#40;CML&#41; is a myeloproliferative disease characterised by clonal expansion of myeloid cells&#46;<span class="elsevierStyleSup">1</span> The pathognomonic cytogenetic anomaly in CML is the Philadelphia chromosome&#44;<span class="elsevierStyleSup">2</span> which is produced by reciprocal translocation of the two long arms of chromosomes 9 and 22&#46;<span class="elsevierStyleSup">3</span> This translocation generates the BC-ABL fusion protein&#44; which is responsible for the oncogenic effects in CML&#46;</p><p class="elsevierStylePara">On only two occasions does the literature describe the use of Imatinib &#40;Gleevec&#44; Novartis&#41;&#44; a BCR-ABL tyrosine kinase inhibitor for CML treatment&#44; in a kidney transplant patient&#59;<span class="elsevierStyleSup">4&#44;5 </span>there are no described cases in a patient with a second transplant with hepatitis C and high cardiovascular and immunological risk&#46;</p><p class="elsevierStylePara"><span class="elsevierStyleBold">CASE REPORT</span></p><p class="elsevierStylePara">Male patient 55 years of age with CML that reached the chronic stage following his second kidney transplant&#46; The patient started haemodialysis for mesangiocapillary glomerulonephritis in 1976 when he was 24&#44; and received a kidney transplant from a live donor in 1983&#46; His immunosupressive treatment was azathioprine and steroids&#46; In 1989&#44; six years after the first transplant&#44; he suffered an acute myocardial infarction&#46; Two years later&#44; he began haemodialysis treatment once again due to chronic rejection of the allograft&#46;</p><p class="elsevierStylePara">In 1994&#44; when the patient was 42&#44; he received a second kidney transplant from a 44 year old female donor&#46; The donor and the recipient share three HLA alleles &#40;HLA A3&#44; B8 and DR3&#41;&#46; The panel reactive antibody &#40;PRA&#41; score was 29&#37;&#44; probably due to various blood transfusions during the course of the first transplant&#44; and to the transplanted organ itself&#46; Immunosuppressants initially administered following the second transplant consisted of steroids &#40;0&#46;5mg&#47;kg&#47;day&#41;&#44; azathioprine &#40;2mg&#47;kg&#47;day&#41; and cyclosporine A &#40;CyA&#41; &#40;10mg&#47;day&#41;&#46;</p><p class="elsevierStylePara">Following the transplant&#44; the patient developed postischaemic acute tubular necrosis&#44; which required two subsequent surgical procedures one month after the transplant to correct a urinary fistula&#46; At the time of the surgical procedure&#44; a kidney biopsy was performed which revealed acute stage 1 rejection&#59; steroids were administered as rescue treatment &#40;1g in four doses&#41;&#46; Two years later&#44; the azathioprine was substituted with mycophenolate &#40;tables 1 and 2&#41; because of decreased renal function with CyA&#46;</p><p class="elsevierStylePara">The patient&#191;s progress was satisfactory until June 2000&#44; when a routine analysis revealed significant leukocytosis &#40;34&#46;5 x 109&#47;l&#41; and thrombocytosis &#40;487 x 109&#47;l&#41; &#40;figure 1&#41;&#46; The patient experienced bilateral hip pain&#44; but had no other symptoms&#46; The examination was normal with no signs of spleen or liver enlargement&#46;</p><p class="elsevierStylePara">An MRI scan of the hip showed diffused bone marrow involvement in almost all bones&#46; The bone marrow aspiration and biopsy confirmed granulocytic and megakaryocytic hyperplasia compatible with CML&#46; No fibrosis was observed in the bone marrow and the patient was low-risk according to the Sokal index&#46;</p><p class="elsevierStylePara">The presence of the Philadelphia chromosome &#40;46XY t&#91;9&#59;22&#93;&#91;q34&#59;q11&#93;&#41; was detected by analysing the bone marrow karyotype&#46; Subsequent cytogenic molecular analyses with fluorescent in situ hybridation &#40;FISH&#41; revealed the presence of the BCR-ABL fusion gene in 90&#37; of the nuclei&#46; The RT-PCR confirmed the typical rearrangement of p210 BCR-ABL with the fusion transcript b2a2&#46; During two months&#44; the patient was treated with hydroxyurea&#44; with no results&#46; In September of this year&#44; the patient was placed in a clinical trial of Novartis STI571-0113 and received 400mg of Imatinib daily&#59; he showed a good tolerance of the drug with no adverse effects&#46; The patient went into complete&#44; sustained haematological remission&#44; complete cytogenetic remission&#44; and molecular remission at two&#44; six and nine months respectively&#44; and this continues to be the case today &#40;figure 2&#41;&#46; Fourteen years after his second transplant&#44; the patient maintains an acceptable level of renal function &#40;stage III chronic renal disease&#41; and has not experienced acute rejection&#44; decreased hepatic function or new cardiovascular events &#40;table 1&#41;&#46;</p><p class="elsevierStylePara"><span class="elsevierStyleBold">DISCUSSION</span></p><p class="elsevierStylePara">This case shows that Imatinib is a safe&#44; effective drug for the treatment of CML in kidney transplant patients&#46; Our patient responded rapidly to the treatment&#58; peripheral blood and bone marrow became normal in the first two months&#44; and cytogenetic and molecular remission occurred during the first year of treatment&#46; These results are in line with IRIS1 study&#44; which showed a complete cytogenetic response in 89&#37; of patients with a low Sokal index&#44; and a survival rate of 83&#37;&#46; Lastly&#44; that study and our patient&#191;s case both show that an early cytogenetic and molecular response is associated with better long-term evolution and a lower risk of progression to the accelerated phase or blast crisis&#46;<span class="elsevierStyleSup">6</span></p><p class="elsevierStylePara">The use of Imatinib in this patient may also have had a beneficial immunosuppressant effect for the transplanted kidney&#44; as suggested by recent in-vitro and animal studies showing that this drug may have immunomodulating effects&#46; Appel et al&#46; showed that Imatinib can inhibit the differentiation of CD34&#43; stem cells into dendritic cells &#40;DC&#41;&#46; Furthermore&#44; T-cell activation may be inhibited&#44; since DC cells&#191; secretion of cytokines and chemokines decreases&#46;<span class="elsevierStyleSup">7</span> Imatinib also inhibits the development of monocytes and macrophages in bone marrow progenitor cells&#46;<span class="elsevierStyleSup">8 </span>Lastly&#44; Dietz et al&#46; showed that Imatinib can inhibit T-cell proliferation by arresting the proliferation of lymphocytes in G<span class="elsevierStyleInf">0</span> phase&#46;</p><p class="elsevierStylePara">Some studies suggest that imatinib in the presence of cyclosporine can cause renal failure due to acute tubular necrosis&#46;<span class="elsevierStyleSup">10&#44;11</span> Despite receiving both drugs&#44; our patient&#191;s renal function remained stable from the moment when treatment with Imatinib was started&#46; Creatinine levels oscillated between 1&#46;75 and 2&#46;4mg&#47;dl with low levels of proteinuria &#40;the maximum proteinuria level was 0&#46;56g&#47;dl&#41;&#44; &#40;table 1&#41;&#46;</p><p class="elsevierStylePara">Serious hepatic side effects have also been described&#44; including fulminant liver failure associated with imatinib treatment&#46;<span class="elsevierStyleSup">12-15</span> Our patient&#44; who was positive for HCV&#44; experienced no changes in liver function during treatment&#46; Liver function remained within the normal range at all times&#44; despite having detectable HCV RNA in blood plasma&#44; which tends to be the case for most HCV patients following a transplant&#46;<span class="elsevierStyleSup">16</span> &#40;Table 3&#41;&#46;</p><p class="elsevierStylePara">Imatinib&#44; according to the manufacturer&#44; may have adverse effects in cardiac patients due to the risk of heart failure&#46; Our patient&#44; who suffered a myocardial infarction at the age of 37&#44; has experienced no adverse effects and his cardiac stress test this year was normal&#46;</p><p class="elsevierStylePara">We conclude that imatinib is a safe and effective treatment for kidney transplant patients with CML&#46; Furthermore&#44; in vitro and animal studies suggest that the drug may have immunomodulating effects that could be beneficial for a transplant&#46; <br></br></p><p class="elsevierStylePara"><a href="grande&#47;45118078&#95;f1&#95;p605&#46;jpg" class="elsevierStyleCrossRefs"><img src="45118078_f1_p605.jpg"></img></a></p><p class="elsevierStylePara">Figure 1&#46; </p><p class="elsevierStylePara"><a href="grande&#47;45118078&#95;t1&#95;p606&#46;jpg" class="elsevierStyleCrossRefs"><img src="45118078_t1_p606.jpg" alt="Patient&#39;s renal function over the last 13 years"></img></a></p><p class="elsevierStylePara">Table 1&#46; Patient&#39;s renal function over the last 13 years</p><p class="elsevierStylePara"><a href="grande&#47;45118078&#95;t2&#95;606&#46;jpg" class="elsevierStyleCrossRefs"><img src="45118078_t2_606.jpg" alt="Creatinine&#44; cyclosporin &#40;CyA&#41; and mycophenolate &#40;MMF&#41; levels during treatment with imatinib"></img></a></p><p class="elsevierStylePara">Table 2&#46; Creatinine&#44; cyclosporin &#40;CyA&#41; and mycophenolate &#40;MMF&#41; levels during treatment with imatinib</p><p class="elsevierStylePara"><a href="grande&#47;45118078&#95;t3&#95;p606&#46;jpg" class="elsevierStyleCrossRefs"><img src="45118078_t3_p606.jpg" alt="Liver function and hep C status from one month after starting treatment"></img></a></p><p class="elsevierStylePara">Table 3&#46; Liver function and hep C status from one month after starting treatment</p><p class="elsevierStylePara"><a href="grande&#47;45118078&#95;f2&#95;p607&#46;jpg" class="elsevierStyleCrossRefs"><img src="45118078_f2_p607.jpg"></img></a></p><p class="elsevierStylePara">Figure 2&#46; </p>"
    "pdfFichero" => "P-E-S-A451-EN.pdf"
    "tienePdf" => true
    "PalabrasClave" => array:2 [
      "en" => array:2 [
        0 => array:4 [
          "clase" => "keyword"
          "titulo" => "Keywords"
          "identificador" => "xpalclavsec438219"
          "palabras" => array:1 [
            0 => "Chronic myeloid leukemia"
          ]
        ]
        1 => array:4 [
          "clase" => "keyword"
          "titulo" => "Keywords"
          "identificador" => "xpalclavsec438221"
          "palabras" => array:1 [
            0 => "renal transplant"
          ]
        ]
      ]
      "es" => array:2 [
        0 => array:4 [
          "clase" => "keyword"
          "titulo" => "Palabras clave"
          "identificador" => "xpalclavsec438220"
          "palabras" => array:1 [
            0 => "trasplante renal"
          ]
        ]
        1 => array:4 [
          "clase" => "keyword"
          "titulo" => "Palabras clave"
          "identificador" => "xpalclavsec438222"
          "palabras" => array:1 [
            0 => "Leucemia mieloide cr&#243;nica"
          ]
        ]
      ]
    ]
    "tieneResumen" => true
    "resumen" => array:2 [
      "en" => array:1 [
        "resumen" => "Abstract Chronic myeloid leukemia &#40;CML&#41; is a myeloproliferative disorder characterized by clonal expansion of cells in the myeloid line&#44; expressing the BCRABL fusion protein responsible for the oncogenic effect of CML&#46; The current frontline therapy in CML is the BCR-ABL tyrosine kinase inhibitor&#44; Imatinib&#46; Although this drug has been shown to improve survival in CML patients&#44; its role in the context of a transplant setting has not been widely described in the literature&#46; We report on the long term molecular remission of CML in a 55 year old man with a second renal transplant who is hepatitis C virus positive&#44; and has associated cardiovascular and immunological risk factors&#46;"
      ]
      "es" => array:1 [
        "resumen" => "<p class="elsevierStylePara">La leucemia mieloide cr&#243;nica &#40;LMC&#41; es una enfermedad mieloproliferativa caracterizada por la expansi&#243;n clonal de c&#233;lulas mieloides que expresan la prote&#237;na de fusi&#243;n BCR-ABL&#44; responsable de los efectos oncog&#233;nicos de la LMC&#46; La terapia actual en el tratamiento de LMC es el inhibidor de la BCR-ABL tiros&#237;n-kinasa&#44; imatinib&#46; Aunque este f&#225;rmaco ha demostrado mejorar la supervivencia en pacientes con LMC&#44; su papel en el contexto del trasplante renal no ha sido ampliamente descrito en la literatura&#46; Presentamos un caso de remisi&#243;n molecular de LMC en un var&#243;n de 55 a&#241;os con un segundo trasplante renal&#44; hepatitis C y con riesgos cardiovasculares e inmunol&#243;gicos asociados&#46;</p>"
      ]
    ]
    "multimedia" => array:5 [
      0 => array:7 [
        "identificador" => "fig1"
        "etiqueta" => "Fig. 1"
        "tipo" => "MULTIMEDIAFIGURA"
        "mostrarFloat" => true
        "mostrarDisplay" => false
        "copyright" => "Elsevier Espa&#241;a"
        "figura" => array:1 [
          0 => array:4 [
            "imagen" => "45118078_f1_p605.jpg"
            "Alto" => 372
            "Ancho" => 825
            "Tamanyo" => 29019
          ]
        ]
      ]
      1 => array:8 [
        "identificador" => "fig2"
        "etiqueta" => "Tab.  1"
        "tipo" => "MULTIMEDIAFIGURA"
        "mostrarFloat" => true
        "mostrarDisplay" => false
        "copyright" => "Elsevier Espa&#241;a"
        "figura" => array:1 [
          0 => array:4 [
            "imagen" => "45118078_t1_p606.jpg"
            "Alto" => 134
            "Ancho" => 826
            "Tamanyo" => 23808
          ]
        ]
        "descripcion" => array:1 [
          "en" => "Patient&#39;s renal function over the last 13 years"
        ]
      ]
      2 => array:8 [
        "identificador" => "fig3"
        "etiqueta" => "Tab.  2"
        "tipo" => "MULTIMEDIAFIGURA"
        "mostrarFloat" => true
        "mostrarDisplay" => false
        "copyright" => "Elsevier Espa&#241;a"
        "figura" => array:1 [
          0 => array:4 [
            "imagen" => "45118078_t2_606.jpg"
            "Alto" => 156
            "Ancho" => 826
            "Tamanyo" => 29652
          ]
        ]
        "descripcion" => array:1 [
          "en" => "Creatinine&#44; cyclosporin &#40;CyA&#41; and mycophenolate &#40;MMF&#41; levels during treatment with imatinib"
        ]
      ]
      3 => array:8 [
        "identificador" => "fig4"
        "etiqueta" => "Tab.  3"
        "tipo" => "MULTIMEDIAFIGURA"
        "mostrarFloat" => true
        "mostrarDisplay" => false
        "copyright" => "Elsevier Espa&#241;a"
        "figura" => array:1 [
          0 => array:4 [
            "imagen" => "45118078_t3_p606.jpg"
            "Alto" => 233
            "Ancho" => 827
            "Tamanyo" => 40890
          ]
        ]
        "descripcion" => array:1 [
          "en" => "Liver function and hep C status from one month after starting treatment"
        ]
      ]
      4 => array:7 [
        "identificador" => "fig5"
        "etiqueta" => "Fig. 2"
        "tipo" => "MULTIMEDIAFIGURA"
        "mostrarFloat" => true
        "mostrarDisplay" => false
        "copyright" => "Elsevier Espa&#241;a"
        "figura" => array:1 [
          0 => array:4 [
            "imagen" => "45118078_f2_p607.jpg"
            "Alto" => 368
            "Ancho" => 824
            "Tamanyo" => 25738
          ]
        ]
      ]
    ]
    "bibliografia" => array:2 [
      "titulo" => "Bibliography"
      "seccion" => array:1 [
        0 => array:1 [
          "bibliografiaReferencia" => array:16 [
            0 => array:3 [
              "identificador" => "bib1"
              "etiqueta" => "1"
              "referencia" => array:1 [
                0 => array:3 [
                  "referenciaCompleta" => "Druker BJ, Talpaz M, Resta DJ, Peng B, Buchdunger E, Ford JM, et al. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med 2001;344(14):1031-7. <a href="http://www.ncbi.nlm.nih.gov/pubmed/11287972" target="_blank">[Pubmed]</a>"
                  "contribucion" => array:1 [
                    0 => null
                  ]
                  "host" => array:1 [
                    0 => array:1 [
                      "Revista" => array:1 [
                        "itemHostRev" => array:3 [
                          "pii" => "S1525861013000388"
                          "estado" => "S300"
                          "issn" => "15258610"
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            1 => array:3 [
              "identificador" => "bib2"
              "etiqueta" => "2"
              "referencia" => array:1 [
                0 => array:3 [
                  "referenciaCompleta" => "Nowell PC, Hungerford DA. Chromosome studies in human leukemia. II. Chronic granulocytic leukemia. J Natl Cancer Inst 1961;27:1013-35. <a href="http://www.ncbi.nlm.nih.gov/pubmed/14480645" target="_blank">[Pubmed]</a>"
                  "contribucion" => array:1 [
                    0 => null
                  ]
                  "host" => array:1 [
                    0 => null
                  ]
                ]
              ]
            ]
            2 => array:3 [
              "identificador" => "bib3"
              "etiqueta" => "3"
              "referencia" => array:1 [
                0 => array:3 [
                  "referenciaCompleta" => "Rowley JD. Letter: A new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and Giemsa staining. Nature 1973;243(5405):290-3. <a href="http://www.ncbi.nlm.nih.gov/pubmed/4126434" target="_blank">[Pubmed]</a>"
                  "contribucion" => array:1 [
                    0 => null
                  ]
                  "host" => array:1 [
                    0 => null
                  ]
                ]
              ]
            ]
            3 => array:3 [
              "identificador" => "bib4"
              "etiqueta" => "4"
              "referencia" => array:1 [
                0 => array:3 [
                  "referenciaCompleta" => "Koca E, Cetiner D, Goker H, Aksu S, Ozcebe OI, Haznedaroglu IC, et al. Complete cytogenietic remission with imatinib mesylate treatment in chronic myelogenous leukemia (CML) developed after renal transplantation Clin Nephrol 2005;64(4):324-6. <a href="http://www.ncbi.nlm.nih.gov/pubmed/16240908" target="_blank">[Pubmed]</a>"
                  "contribucion" => array:1 [
                    0 => null
                  ]
                  "host" => array:1 [
                    0 => null
                  ]
                ]
              ]
            ]
            4 => array:3 [
              "identificador" => "bib5"
              "etiqueta" => "5"
              "referencia" => array:1 [
                0 => array:3 [
                  "referenciaCompleta" => "Thierry A, Dreyfus B, Bridoux F, Abou Ayache R, Milin S, Guilhot F, et al. Long-term molecular efficacy and safety of imatinib in a patient with chronic myeloid leukaemia after renal transplantation. Nephrol Dial Transplant 2007;22(6):1791-2. <a href="http://www.ncbi.nlm.nih.gov/pubmed/17308316" target="_blank">[Pubmed]</a>"
                  "contribucion" => array:1 [
                    0 => null
                  ]
                  "host" => array:1 [
                    0 => null
                  ]
                ]
              ]
            ]
            5 => array:3 [
              "identificador" => "bib6"
              "etiqueta" => "6"
              "referencia" => array:1 [
                0 => array:3 [
                  "referenciaCompleta" => "Druker BJ, Guilhot F, O¿Brien SG, Gathmann I, Kantarjian H, Gattermann N, et al.; IRIS Investigators. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med 2006;355(23):2408-17. <a href="http://www.ncbi.nlm.nih.gov/pubmed/17151364" target="_blank">[Pubmed]</a>"
                  "contribucion" => array:1 [
                    0 => null
                  ]
                  "host" => array:1 [
                    0 => null
                  ]
                ]
              ]
            ]
            6 => array:3 [
              "identificador" => "bib7"
              "etiqueta" => "7"
              "referencia" => array:1 [
                0 => array:3 [
                  "referenciaCompleta" => "Appel S, Balabanov S, Brümmendorf TH, Brossart P. Effects of imatinib on normal hematopoiesis and immune activation. Stem Cells 2005;23(8):1082-8. <a href="http://www.ncbi.nlm.nih.gov/pubmed/16140870" target="_blank">[Pubmed]</a>"
                  "contribucion" => array:1 [
                    0 => null
                  ]
                  "host" => array:1 [
                    0 => null
                  ]
                ]
              ]
            ]
            7 => array:3 [
              "identificador" => "bib8"
              "etiqueta" => "8"
              "referencia" => array:1 [
                0 => array:3 [
                  "referenciaCompleta" => "Dewar AL, Doherty KV, Hughes TP, Lyons AB. Imatinib inhibits the functional capacity of cultured human monocytes. Immunol Cell Biol 2005;83(1):48-56. <a href="http://www.ncbi.nlm.nih.gov/pubmed/15661041" target="_blank">[Pubmed]</a>"
                  "contribucion" => array:1 [
                    0 => null
                  ]
                  "host" => array:1 [
                    0 => null
                  ]
                ]
              ]
            ]
            8 => array:3 [
              "identificador" => "bib9"
              "etiqueta" => "9"
              "referencia" => array:1 [
                0 => array:3 [
                  "referenciaCompleta" => "Dietz AB, Souan L, Knutson GJ, Bulur PA, Litzow MR, Vuk-Pavlovic S. Imatinib mesylate inhibits T-cell proliferation in vitro and delayed-type hypersensitivity in vivo. Blood 2004;104(4):1094-9. <a href="http://www.ncbi.nlm.nih.gov/pubmed/15100154" target="_blank">[Pubmed]</a>"
                  "contribucion" => array:1 [
                    0 => null
                  ]
                  "host" => array:1 [
                    0 => null
                  ]
                ]
              ]
            ]
            9 => array:3 [
              "identificador" => "bib10"
              "etiqueta" => "10"
              "referencia" => array:1 [
                0 => array:3 [
                  "referenciaCompleta" => "Kitiyakara C, Atichartakarn V. Renal failure associated with a specific inhibitor of BCR-ABL tyrosine kinase, STI 571. Nephrol Dial Transplant 2002;17(4):685-7."
                  "contribucion" => array:1 [
                    0 => null
                  ]
                  "host" => array:1 [
                    0 => null
                  ]
                ]
              ]
            ]
            10 => array:3 [
              "identificador" => "bib11"
              "etiqueta" => "11"
              "referencia" => array:1 [
                0 => array:3 [
                  "referenciaCompleta" => "Pou M, Saval N, Vera M, Saurina A, Solé M, Cervantes F, et al. Acute renal failure secondary to imatinib mesylate treatment in chronic myeloid leukemia. Leuk Lymphoma 2003;44(7):1239-41. <a href="http://www.ncbi.nlm.nih.gov/pubmed/12916879" target="_blank">[Pubmed]</a>"
                  "contribucion" => array:1 [
                    0 => null
                  ]
                  "host" => array:1 [
                    0 => null
                  ]
                ]
              ]
            ]
            11 => array:3 [
              "identificador" => "bib12"
              "etiqueta" => "12"
              "referencia" => array:1 [
                0 => array:3 [
                  "referenciaCompleta" => "Chen L, Wang JM, Xu XP Gao L, Fei XH, Lou JW, et al. The reverse effect on drug-resistance against tyrosine kinase inhibitor STI571 in mdr1 and bcr-abl positive leukemic cells. Zhongguo Shi Yan Xue Ye Xue Za Zhi (Abstract) 2003;11(6):600-3."
                  "contribucion" => array:1 [
                    0 => null
                  ]
                  "host" => array:1 [
                    0 => array:1 [
                      "Revista" => array:1 [
                        "itemHostRev" => array:3 [
                          "pii" => "S1525861011002568"
                          "estado" => "S300"
                          "issn" => "15258610"
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            12 => array:3 [
              "identificador" => "bib13"
              "etiqueta" => "13"
              "referencia" => array:1 [
                0 => array:3 [
                  "referenciaCompleta" => "Ridruejo E, Cacchione R, Villamil AG, Marciano S, Gadano AC, Mando OG. Imatinib-induced fatal acute liver failure. World J Gastroenterol 2007;13(48):6608-11."
                  "contribucion" => array:1 [
                    0 => null
                  ]
                  "host" => array:1 [
                    0 => null
                  ]
                ]
              ]
            ]
            13 => array:3 [
              "identificador" => "bib14"
              "etiqueta" => "14"
              "referencia" => array:1 [
                0 => array:3 [
                  "referenciaCompleta" => "Cross TJ, Bagot C, Portmann B, Wendon J, Gillett D. Imatinib mesylate as a cause of acute liver failure. Am J Hematol 2006;81(3):189-92. <a href="http://www.ncbi.nlm.nih.gov/pubmed/16493605" target="_blank">[Pubmed]</a>"
                  "contribucion" => array:1 [
                    0 => null
                  ]
                  "host" => array:1 [
                    0 => array:1 [
                      "Revista" => array:1 [
                        "itemHostRev" => array:3 [
                          "pii" => "S1525861013003022"
                          "estado" => "S300"
                          "issn" => "15258610"
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            14 => array:3 [
              "identificador" => "bib15"
              "etiqueta" => "15"
              "referencia" => array:1 [
                0 => array:3 [
                  "referenciaCompleta" => "Al Sobhi E, Zahrani Z, Zevallos E, Zuraiki A. Imatinib-induced immune hepatitis: case report and literature review. Hematology 2007;12(1):49-53. <a href="http://www.ncbi.nlm.nih.gov/pubmed/17364993" target="_blank">[Pubmed]</a>"
                  "contribucion" => array:1 [
                    0 => null
                  ]
                  "host" => array:1 [
                    0 => null
                  ]
                ]
              ]
            ]
            15 => array:3 [
              "identificador" => "bib16"
              "etiqueta" => "16"
              "referencia" => array:1 [
                0 => array:3 [
                  "referenciaCompleta" => "Morales JM, Campistol JM.Transplantation in the Patient with Hepatitis C. J Am Soc Nephrol 2000;11:1343-53.  <a href="http://www.ncbi.nlm.nih.gov/pubmed/10864593" target="_blank">[Pubmed]</a>"
                  "contribucion" => array:1 [
                    0 => null
                  ]
                  "host" => array:1 [
                    0 => null
                  ]
                ]
              ]
            ]
          ]
        ]
      ]
    ]
  ]
  "idiomaDefecto" => "en"
  "url" => "/20132514/0000002900000006/v0_201502091611/X2013251409033669/v0_201502091612/en/main.assets"
  "Apartado" => array:4 [
    "identificador" => "35422"
    "tipo" => "SECCION"
    "en" => array:2 [
      "titulo" => "Case Reports"
      "idiomaDefecto" => true
    ]
    "idiomaDefecto" => "en"
  ]
  "PDF" => "https://static.elsevier.es/multimedia/20132514/0000002900000006/v0_201502091611/X2013251409033669/v0_201502091612/en/P-E-S-A451-EN.pdf?idApp=UINPBA000064&text.app=https://revistanefrologia.com/"
  "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/X2013251409033669?idApp=UINPBA000064"
]
Article information
ISSN: 20132514
Original language: English
The statistics are updated each day
Year/Month Html Pdf Total
2024 November 6 6 12
2024 October 78 47 125
2024 September 60 44 104
2024 August 66 88 154
2024 July 47 45 92
2024 June 75 52 127
2024 May 71 46 117
2024 April 71 44 115
2024 March 55 36 91
2024 February 53 49 102
2024 January 44 36 80
2023 December 51 28 79
2023 November 58 37 95
2023 October 69 58 127
2023 September 85 33 118
2023 August 54 30 84
2023 July 45 31 76
2023 June 43 20 63
2023 May 48 33 81
2023 April 36 16 52
2023 March 45 24 69
2023 February 35 31 66
2023 January 35 25 60
2022 December 42 24 66
2022 November 49 33 82
2022 October 43 53 96
2022 September 31 30 61
2022 August 60 44 104
2022 July 31 46 77
2022 June 42 26 68
2022 May 47 29 76
2022 April 43 42 85
2022 March 30 36 66
2022 February 42 40 82
2022 January 41 22 63
2021 December 34 38 72
2021 November 37 39 76
2021 October 39 45 84
2021 September 28 28 56
2021 August 32 32 64
2021 July 38 33 71
2021 June 31 18 49
2021 May 30 25 55
2021 April 76 31 107
2021 March 37 12 49
2021 February 36 16 52
2021 January 61 16 77
2020 December 61 12 73
2020 November 42 7 49
2020 October 29 11 40
2020 September 27 5 32
2020 August 38 7 45
2020 July 30 10 40
2020 June 27 12 39
2020 May 43 8 51
2020 April 34 16 50
2020 March 38 7 45
2020 February 35 18 53
2020 January 39 15 54
2019 December 46 21 67
2019 November 71 22 93
2019 October 31 13 44
2019 September 28 18 46
2019 August 26 17 43
2019 July 47 22 69
2019 June 34 12 46
2019 May 51 13 64
2019 April 69 30 99
2019 March 25 21 46
2019 February 19 16 35
2019 January 26 12 38
2018 December 68 27 95
2018 November 49 15 64
2018 October 55 8 63
2018 September 59 8 67
2018 August 40 16 56
2018 July 49 12 61
2018 June 41 12 53
2018 May 56 14 70
2018 April 31 4 35
2018 March 55 6 61
2018 February 43 6 49
2018 January 39 7 46
2017 December 54 10 64
2017 November 41 5 46
2017 October 36 8 44
2017 September 40 8 48
2017 August 58 36 94
2017 July 52 15 67
2017 June 47 13 60
2017 May 63 6 69
2017 April 49 6 55
2017 March 44 4 48
2017 February 29 8 37
2017 January 26 1 27
2016 December 64 4 68
2016 November 85 5 90
2016 October 108 10 118
2016 September 156 6 162
2016 August 195 4 199
2016 July 172 5 177
2016 June 120 0 120
2016 May 140 0 140
2016 April 84 0 84
2016 March 77 0 77
2016 February 85 0 85
2016 January 74 0 74
2015 December 120 0 120
2015 November 89 0 89
2015 October 96 0 96
2015 September 86 0 86
2015 August 60 0 60
2015 July 63 0 63
2015 June 38 0 38
2015 May 46 0 46
2015 April 6 0 6
Show all

Follow this link to access the full text of the article

Idiomas
Nefrología (English Edition)
es en

¿Es usted profesional sanitario apto para prescribir o dispensar medicamentos?

Are you a health professional able to prescribe or dispense drugs?